Evaxion Biotech, along with UMass Chan Medical School, has received a funding from the US National Institutes of Health (NIH) to develop a lead vaccine candidate to treat gonorrhea.
CARsgen Therapeutics has announced the start of production at its Current Good Manufacturing Practice (CGMP) manufacturing facility in North Carolina, US and released the first CAR T cells batch for clinical trials.
BioDuro-Sundia and X-Chem have collaborated to launch the DNA encoded compound library (DEL) technology services in China for the discovery of new small molecule drugs.
Kiniksa Pharmaceuticals has entered into a global license agreement with Roche and its subsidiary, Genentech, for the development and commercialisation of an investigational fully human monoclonal antibody, vixarelimab.
ViiV Healthcare and the Medicines Patent Pool (MPP) have entered into a voluntary licensing agreement to expand access to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).
Procaps Group, an integrated LatAm healthcare and pharmaceutical conglomerate, has signed a definitive agreement to buy Grupo Somar, which includes Grupo Farmacéutico Somar and Química y Farmacia and, Gelcaps and associated entities from Advent International, a private equity investor.
Artax Biopharma is set to develop its first oral small molecule immunomodulating agent, AX-158, after it closed a $26m financing round.
Asahi Kasei Medical’s US subsidiary has signed an agreement to acquire Bionova Scientific for an undisclosed amount.
Clovis Oncology and Evergreen Theragnostics have initiated a development, manufacturing, and services agreement for actinium-225-labeled-FAP-2286 (225Ac-FAP-2286).
Luye Pharma Group’s wholly owned subsidiary Yantai Luye Drugs Trading has collaborated with Beijing Biostar Pharmaceuticals’ subsidiary Chengdu Biostar Pharmaceuticals for marketing anticancer drug, Utidelone Injection, in Chinese mainland.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.